In:
Pharmacogenomics, Future Medicine Ltd, Vol. 15, No. 4 ( 2014-03), p. 449-457
Abstract:
Aim: This study aimed to identify prognostic factors of aspirin-exacerbated respiratory disease by comparing clinical and genetic data with the clinical course. Patients & methods: Patients were classified into two groups according to their response to inhalation rechallenge with lysine-aspirin after at least 1 year of regular treatment with antiasthmatic medications. Results: Forty eight patients (39.3%, group I) had negative responses, whereas 74 patients (60.7%, group II) had positive responses (n = 23) or were not rechallenged owing to persistent symptoms (n = 51). FEV 1 at diagnosis and follow-up were significantly lower in group II than in group I. The CCR3 polymorphism at -520T/G differed significantly between the two groups, whereas no difference was found in other SNPs. Conclusion: Baseline FEV 1 and lower lung function after treatment were clinical factors indicating a poor prognosis of aspirin-exacerbated respiratory disease. The G allele of CCR3 -520T 〉 G was associated with persistent bronchial hypersensitivity to aspirin. Original submitted 17 June 2013; Revision 3 January 2014
Type of Medium:
Online Resource
ISSN:
1462-2416
,
1744-8042
Language:
English
Publisher:
Future Medicine Ltd
Publication Date:
2014
SSG:
15,3
Permalink
